Want to see GB:VRCI full AI Analyst Report?
Top Page
Verici Dx Plc
(LSE:VRCI)
Select Model
Select Model
Rating:44Neutral
Price Target:
0.23 p
▲(3.64% Upside)
Action:Reiterated
Date:10/17/26
The score is held down primarily by weak financial performance driven by sizable losses and worsening cash burn despite strong revenue growth. Technicals add modest support from short-term strength, but longer-term trend signals remain weak. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Revenue Growth
Rapid revenue expansion indicates increasing commercial adoption of Verici Dx’s transplant-focused diagnostic products. If sustained, the larger revenue base can improve operating leverage, support broader clinical uptake, and create a stronger foundation for future profitability.
Negative Factors
Persistent Net Losses
Sizable and persistent net losses show that revenue growth has not yet translated into a sustainable earnings model. The widening 2025 loss increases the distance to profitability and may constrain internal reinvestment, making future financial progress dependent on stronger operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Rapid revenue expansion indicates increasing commercial adoption of Verici Dx’s transplant-focused diagnostic products. If sustained, the larger revenue base can improve operating leverage, support broader clinical uptake, and create a stronger foundation for future profitability.
Read all positive factors
Verici Dx Plc (VRCI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£15.32M
Dividend YieldN/A
Average Volume (3M)14.99M
Price to Earnings (P/E)―
Beta (1Y)-1.43
Revenue Growth77.87%
EPS Growth84.36%
CountryUK
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,662,311,500
10 Day Avg. Volume20,744,305
30 Day Avg. Volume14,993,222
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.20
Price to Sales (P/S)2.08
P/FCF Ratio-0.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.90M
Verici Dx Plc Business Overview & Revenue Model
Company Description
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipel...
Verici Dx Plc Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.50M | 3.74M | 3.34M | 1.01M | 0.00 | 0.00 |
| Gross Profit | 1.97M | 2.32M | 3.34M | 1.01M | 0.00 | 0.00 |
| EBITDA | -7.17M | ― | -5.15M | -7.88M | -10.50M | -7.15M |
| Net Income | -7.82M | -7.08M | -5.87M | -8.73M | -11.36M | -8.33M |
Balance Sheet | ||||||
| Total Assets | 8.19M | 7.94M | 7.49M | 7.44M | 14.30M | 13.79M |
| Cash, Cash Equivalents and Short-Term Investments | 2.41M | 3.34M | 4.06M | 2.65M | 9.80M | 10.34M |
| Total Debt | 776.01K | 197.07K | 371.00K | 540.00K | 700.00K | 0.00 |
| Total Liabilities | 2.45M | 1.44M | 2.23M | 3.88M | 2.80M | 1.80M |
| Stockholders Equity | 5.75M | 6.51M | 5.26M | 3.56M | 11.51M | 11.98M |
Cash Flow | ||||||
| Free Cash Flow | -8.35M | -8.39M | -6.21M | -7.39M | -11.38M | -7.30M |
| Operating Cash Flow | -8.34M | -8.39M | -6.02M | -7.16M | -10.07M | -6.34M |
| Investing Cash Flow | -222.62K | -192.97K | 61.00K | -231.00K | -1.31M | -965.86K |
| Financing Cash Flow | 10.75M | 7.87M | 7.32M | -27.00K | 12.67M | -73.55K |
Verici Dx Plc Technical Analysis
Positive
0.22
Price Trends
0.22
Positive
0.27
Negative
0.41
Negative
Market Momentum
>-0.01
Negative
56.48
Neutral
40.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Positive. The current price of 0.22 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.22, and below the 200-day MA of 0.41, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 56.48 is Neutral, neither overbought nor oversold. The STOCH value of 40.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VRCI.
Verici Dx Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | £102.71M | 41.38 | 3.58% | 4.36% | 2.26% | -57.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% | |
46 Neutral | £22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% | |
44 Neutral | £15.32M | -0.60 | -127.57% | ― | 77.87% | 84.36% | |
40 Underperform | £14.45M | -0.27 | -451.74% | ― | 33.37% | 86.41% | |
40 Underperform | £36.54M | -3.44 | 675.00% | ― | ― | ― |
* Healthcare Sector Average
GB:VRCI
Verici Dx Plc
0.23
-0.47
-67.14%
GB:EKF
EKF Diagnostics Holdings
24.00
-2.35
-8.92%
GB:GDR
Genedrive
0.98
-0.06
-5.43%
GB:OBD
Oxford BioDynamics
0.11
-0.21
-66.56%
GB:RENX
Renalytix
5.45
-2.80
-33.94%
GB:ABDX
Abingdon Health PLC
9.00
2.98
49.50%
Verici Dx Plc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Verici Dx Raises £8.5m Through AIM Placing and Retail Offer
Positive
Oct 13, 2026
Verici Dx plc has completed a WRAP Retail Offer at an issue price of £0.002 per share, raising approximately £250,000 in gross proceeds, which will be accompanied by a much larger institutional placing. Together, the placing and retail o...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Verici Dx Raises £8.75m and Restores AIM Trading After Capital Access Window
Positive
Oct 13, 2026
Verici Dx plc, a developer of AI-driven kidney transplant diagnostics, offers a suite of personalised tests that support clinicians in assessing patient and organ response risk, aiming to improve transplant outcomes. The company’s technology...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Verici Dx Calls General Meeting to Approve New Share Issuance After Fundraising
Positive
Oct 9, 2026
Verici Dx has published a circular and convened a general meeting for 27 October at Shoosmiths LLP in London, aiming to secure shareholder approval for additional share issuance authorities. The move follows a recently announced fundraising and is...
Private Placements and FinancingShareholder Meetings
Verici Dx Opens WRAP Retail Offer Alongside £8.5m Placing
Positive
Oct 9, 2026
Verici Dx has launched a WRAP retail offer to raise up to £250,000 by issuing as many as 125,000,000 new ordinary shares at £0.002 each, matching the price of its recently completed £8.5 million placing. The retail offer is aimed at...
Business Operations and StrategyPrivate Placements and Financing
Verici Dx Raises £8.5m in Oversubscribed Share Placing on AIM
Positive
Oct 9, 2026
Verici Dx has conditionally raised gross proceeds of £8.5 million through a placing of 4.25 billion new shares at 0.20 pence, an 11.1% discount to the pre-suspension market price. The fundraising, supported by both existing and new institutio...
Business Operations and StrategyPrivate Placements and Financing
Verici Dx closes accelerated bookbuild for new share placing
Positive
Oct 9, 2026
Verici Dx plc, a specialist in advanced clinical diagnostics for organ transplant patients, has announced the successful close of its accelerated bookbuild for a share placing. The placing, run with Singer Capital Markets and Oberon Capital as joi...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Verici Dx launches £8m share placing to fund U.S. transplant diagnostics push
Neutral
Oct 8, 2026
Verici Dx plans to raise about £8 million through a heavily dilutive placing of 4 billion new shares at 0.2 pence, alongside a separate UK retail offer of up to £250,000, to bolster its balance sheet and support commercial expansion. The...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Verici Dx to Tap AIM Capital Access Window for New Equity Raise
Positive
Sep 30, 2026
Verici Dx plc, traded on AIM as VRCI, develops AI-assisted clinical diagnostic tests for organ transplantation, centred on a kidney transplant platform that uses transcriptomic analysis to generate RNA-based immune and pathway signatures. These le...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Verici Dx boosts Tutivia growth and expands transplant diagnostics footprint
Positive
Sep 30, 2026
Verici Dx reported H1 2026 revenues of $1.8m, broadly flat year-on-year as prior licensing income rolled off, but with Tutivia testing revenue up more than 50% and testing volumes rising despite a national slowdown in kidney transplants. The group...
Business Operations and StrategyProduct-Related Announcements
Verici Dx to Launch AI-Driven Transplant Genetic Test in Q4 2026
Positive
Sep 21, 2026
Verici Dx plc plans to launch TranscripTx, a first-in-class genetic test for transplant patients, in the fourth quarter of 2026, expanding its portfolio of advanced clinical diagnostics. The test uses next-generation sequencing on peripheral blood...
Business Operations and Strategy
Verici Dx Gains Olink Certification to Expand Proteomics and Biomarker Services
Positive
Aug 11, 2026
Verici Dx has been designated an Olink Certified Service Provider, enabling it to offer Olink-based proteomics assay services from its CAP-certified and CLIA-accredited laboratory. This status allows the company to support biomarker discovery, alg...
Business Operations and StrategyShareholder Meetings
Verici Dx Secures Shareholder Backing as All AGM Resolutions Pass
Positive
Jul 28, 2026
Verici Dx plc, a developer of advanced clinical diagnostics for transplant patients, reported that all resolutions put to shareholders at its latest Annual General Meeting were approved. The strong voting support across resolutions underscores sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.